Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021

As Israeli Firm Publishes Full-Year Results

 
• By Dean Rudge
  
US Flag
Teva's generic operations in the US are worth around $4bn per year in revenues • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Generics

More from Products